二甲双胍在合并代谢综合征的子宫内膜样腺癌中的作用及机制  

Effect and Mechanism of Metformin in Endometrial Adenocarcinoma Patients with Metabolic Syndrome

作　　者：倪镌[1] 寿华锋[1] 楼寒梅[1] 

机构地区：[1]浙江省肿瘤医院妇瘤科,杭州310022

出　　处：《国际妇产科学杂志》2014年第6期603-605,共3页Journal of International Obstetrics and Gynecology

基　　金：浙江省医药卫生科技计划项目(2013KYB045)

摘　　要：二甲双胍作为一线降糖药物,在糖尿病治疗领域发挥重要作用。代谢综合征(MS)是多种代谢物异常集结的病理状态,与其有关的远期不良结局日益受到关注。研究发现,MS各环节与子宫内膜样腺癌发病机制关系密切,两者可能存在共同的病理生理基础——胰岛素抵抗。二甲双胍具有抑制胰岛素抵抗、调节细胞因子水平及独特的抗肿瘤干细胞功能,可能发挥重要的负性调节作用,并可能成为MS人群预防及治疗子宫内膜样腺癌的新型药物。Metformin as the first-line drugs, play an important role in the treatment of diabetes. Metabolic syndrome （MS） is a pathological condition of abnormal aggregation of multiple metabolite resulting. The long-term adverse outcomes were payed more and more attention by people. The study found, MS is recognized risk factor of endometrial adenocarcinoma, there may be a common pathophysiological basis of insulin resistance. Metformin reduces insulin resistance, regulates the level of cytokines and exerts anti-tumor stem cell function, it is a potent inhibitor of metabolic syndrome and endometrial adenocarcinoma.

关 键 词：二甲双胍 代谢综合征X 子宫内膜肿瘤 治疗 

分 类 号：R737.33[医药卫生—肿瘤]